|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miwa M, Ura M, Nishida M, et al: Design of
a novel oral fluoropyrimidine carbamate, capecitabine, which
generates 5-fluorouracil selectively in tumours by enzymes
concentrated in human liver and cancer tissue. Eur J Cancer.
34:1274–1281. 1998. View Article : Google Scholar
|
|
4
|
Shirasaka T, Shimamato Y, Ohshimo H, et
al: Development of a novel form of an oral 5-fluorouracil
derivative (S-1) directed to the potentiation of the tumor
selective cytotoxicity of 5-fluorouracil by two biochemical
modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu RH, Sun GP, Lu HS, et al: A phase III
study of S-1 plus cisplatin versus fluorouracil plus cisplatin in
patients with advanced gastric or gastroesophageal junction
adenocarcinoma. Journal of Clinical Oncology. 31:2013.PubMed/NCBI
|
|
6
|
Muro K, Boku N, Shimada Y, et al:
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid
plus irinotecan (FOLFIRI) as second-line chemotherapy for
metastatic colorectal cancer: a randomised phase 2/3
non-inferiority study (FIRIS study). Lancet Oncol. 11:853–860.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hong YS, Park YS, Lim HY, et al: S-1 plus
oxaliplatin versus capecitabine plus oxaliplatin for first-line
treatment of patients with metastatic colorectal cancer: a
randomised, non-inferiority phase 3 trial. Lancet Oncol.
13:1125–1132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim GM, Jeung HC, Rha SY, et al: A
randomized phase II trial of S-1-oxaliplatin versus
capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer.
48:518–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee JL, Kang YK, Kang HJ, et al: A
randomised multicentre phase II trial of capecitabine vs S-1 as
first-line treatment in elderly patients with metastatic or
recurrent unresectable gastric cancer. Br J Cancer. 99:584–590.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zang DY, Chung IJ, Oh HS, Park KU, Lee KH,
Han B, Choi DR, Kim HS and Kim JH: Randomized phase II study of
oxaliplatin and S-1 (OS) versus oxaliplatin and capecitabine
(XELOX) in patients with metastatic or recurrent colorectal cancer.
J Clin Oncol. 30:5952012.
|
|
11
|
Ba Z, Wu M, Wang LJ and Zhang HQ: Curative
effect analysis of S-1 combined with cisplatin or capecitabine
combined with cisplatin in the treatment of advanced gastric
cancer. Chinese General Practice. 15:672–676. 2012.
|
|
12
|
Lu HM, Zhou LL, Liu JJ and Liu SH:
Clinical study of oxaliplatin plus TS-1 or capecitabine in the
treatment of advanced colon cancer. Cancer Research and Clinic.
24:613–615. 2012.
|
|
13
|
Qiu GQ, Xu LZ, Lin ZC and Chen YQ:
Clinical observation of S-1 in the treatment of old patients with
advanced gastric carcinoma. Chin J Clin Oncol Rehabil. 18:61–63.
2011.
|
|
14
|
Sun DS, Zhang GR, Ma LG and Zou YH: The
comparative effect of capecitabine and
tegafur/gimeracil/oteracil(S-1) on advanced colorectal cancer. Chin
J Prim Med Pharm. 20:826–827. 2013.
|
|
15
|
Xiong HL, Liu XQ, Sun AH, He Y, Li J and
Yuan X: Clinical comparison of docetaxel combined with S-1 or
Capicitabine in treating advanced gastric carcinoma. Modern
Oncology. 21:581–584. 2013.
|
|
16
|
Yan Z, Zhao TX, Xing Y, Chen D and He LL:
Curative effect analysis of S-1 combined with cisplatin in the
treatment of advanced gastric cancer. Progress in Modern
Biomedicine. 12:5324–5326. 2012.
|
|
17
|
Zhang HY and Sun LZ: The clinical study of
domestic compound Tegafur capsule first-line Therapy for patients
with elderly advanced gastric cancer. Medical Innovation of China.
7:94–96. 2010.
|
|
18
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Higgins J and Green S: The Chochrane
Collaboration: Cochrane Handbook for Systematic Reviews of
Interventions. http://www.cochranehandbook.orguri.
Accessed August 31, 20132011
|
|
20
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsuburaya A, Morita S, Kodera Y, et al: A
randomized phase II trial to elucidate the efficacy of capecitabine
plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line
treatment for advanced gastric cancer: XP ascertainment vs. SP
randomized PII trial (XParTS II). BMC Cancer. 12:3072012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okines AFC, Norman AR, McCloud P, Kang YK
and Cunningham D: Meta-analysis of the REAL-2 and ML17032 trials:
evaluating capecitabine-based combination chemotherapy and infused
5-fluorouracil-based combination chemotherapy for the treatment of
advanced oesophago-gastric cancer. Ann Oncol. 20:1529–1534. 2009.
View Article : Google Scholar
|
|
23
|
Huang J, Cao Y, Wu L, Liao C, He Y and Gao
F: S-1-based therapy versus 5-FU-based therapy in advanced gastric
cancer: a meta-analysis. Med Oncol. 28:1004–1011. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma Y, Tang L, Wang HX, Xu YC, Ma Y and
Zhang FC: Capecitabine for the treatment for advanced gastric
cancer: efficacy, safety and ethnicity. J Clin Pharm Ther.
37:266–275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ajani JA, Faust J, Ikeda K, et al: Phase I
pharmacokinetic study of S-1 plus cisplatin in patients with
advanced gastric carcinoma. J Clin Oncol. 23:6957–6965. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kong SY, Lim HS, Nam BH, et al:
Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy
outcomes in metastatic gastric cancer. Pharmacogenomics.
10:1147–1155. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fuse N, Fukuda H, Yamada Y, et al: Updated
results of randomized phase III study of 5-fluorouracil (5-FU)
alone versus combination of irinotecan and cisplatin (CP) versus
S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol
(ASCO Annual Meeting abstracts). 27:45142009.
|
|
28
|
Ajani JA, Rodriguez W, Bodoky G, et al:
Multicenter phase III comparison of cisplatin/S-1 with
cisplatin/infusional fluorouracil in advanced gastric or
gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin
Oncol. 28:1547–1553. 2010. View Article : Google Scholar
|
